No participants were enrolled in the trial.

People with diabetes are at an increased risk of heart attacks and heart failure, and it is important to be able to treat people with diabetes who are at risk for heart disease to prevent these outcomes. This study is looking at the importance of "diffuse scar tissue" that is found in the heart of diabetic people. We have discovered a way to detect diffuse scar tissue by cardiac MRI, a non-invasive test. In this study, we do cardiac MRI on diabetics with low risk stress test results and follow them for 5 years to see if the measure of scar tissue in the heart by MRI is related to events. If this study is positive, we will be able to use cardiac MRI scar tissue measurements to target those patients with diabetes who are at highest risk.

This study will be conducted in TWO (2) PHASES:

Phase 1: Prospective cohort study of patients with diabetes mellitus, in which index cardiac MRI will be done after screening to determine FIBROTIC INDEX. Patients are subsequently followed for 5 years for a primary endpoint (composite cardiovascular event).

Phase 2: Of the patients with "HIGH" FIBROTIC INDEX, 50 patients will be randomly selected and randomized 1:1 to placebo:eplerenone 25 mg daily for 6 months, and a repeat cardiac MRI will be done to assess the fibrotic index post-treatment.

Phase 2 is a PILOT study of 50 patients.

The inclusion/exclusion criteria for the different phases is shown below.

For PHASE I (Prospective Cohort Study to determine prognostic value of fibrotic index)

Inclusion Criteria:

• Diabetes mellitus, type II
• Age >= 40 years
• UKPDS 10 year Risk Score > 15%
• Low risk stress test (defined explicitily in our protocol)

Exclusion Criteria:

• suspected or confirmed myocarditis or infiltrative disease (including hemochromatosis, sarcoid, or amyloid)
• history of prior MI or coronary revascularization (by Q waves on electrocardiogram in 2 contiguous leads or by clinical history)
• clinical HF (with prior hospital admission for HF or documentation of reduced LV ejection fraction after index CMR)
• metallic hazards
• hematocrit < 30% (within 1 year of nuclear stress test) or history of active bleeding (within 3 months of stress test)
• estimated GFR (by Modified Diet in Renal Disease) < 45 ml/min/1.73m2 (within 2 weeks of planned CMR)
• pregnancy
• severe non-cardiac illness that or prognosis (e.g., end stage liver disease, malignancy, advanced HIV/AIDS)

For PHASE 2:

Inclusion Criteria:

• Included in Phase I
• Systolic blood pressure > 140 mmHg on two occasions (at the initial nuclear stress test and at the index cardiac MRI)

Exclusion criteria:

1. Concomitant cytochrome P450 (CYP3A4) inhibitors or inducers;
2. Concomitant potassium supplementation or potassium sparing diuretics;
3. Concomitant use of both ACE inhibitor and ARB therapy (at any dose);
4. Renal dysfunction (GFR < 50 ml/min or serum creatinine > 1.5 mg/dL (as assessed at time of index CMR);
5. Any urine microalbuminuria (as assessed at time of index CMR);
6. Baseline (pre-therapy) serum potassium > 5.0 mEq/L;
7. Lack of reliable telephone contact number for relaying results or the need to discontinue drug therapy;
8. Age > 75 years (given the tendency toward renal insufficiency not captured by GFR, dehydration and/or concomitant illness)
9. Women able to become pregnant (given the undefined risk of eplerenone therapy in pregnant women and newborns).